disadvantaged or medically uninsured. The legislative intent of Section 340B is "to enable * * * certain Federally-funded clinics to obtain lower prices on the drugs that they provide to their patients."

A customer survey is being developed to collect information by mail on

various aspects of the program, including, for example, whether information on the program is reaching the covered entities, reasons some entities are not participating, satisfaction with the savings realized, and interest in possible modifications to

the program. Both participating and nonparticipating entities will be included in the survey. The results will be used to improve the design and management of the program. Burden estimates are as follows:

Respondents	Number of respondents	Responses per respondent	Burden per response	Total bur- den hours
Covered Entities	925	1	.25	231.

Send comments to Patricia Royston, HRSA Reports Clearance Officer, Room 14–36, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice.

Dated: August 14, 1996.

J. Henry Montes,

Associate Administrator for Policy

Coordination.

[FR Doc. 96–21141 Filed 8–19–96; 8:45 am]

BILLING CODE 4160–15–P

National Institutes of Health

Proposed Collection; Comment Request; Women's Health and Aging Study—Telephone Follow-up

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Institute on Aging (NIA), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

PROPOSED COLLECTION: Title: Women's Health and Aging Study—Telephone Follow-up. Type of Information Collection Request: Revision. Need and Use of Information Collection: This proposed study is designed to obtain additional data on women (previously examined in the Women's Health and Aging Study, OMB No. 0925-0376, expiration 8/31/97) through telephone interviews with participants or their proxies 1 and 2 years after their final inhome contacts. The Women's Health and Aging Study (WHAS) is a community-based prospective epidemiologic study whose goal is to study the causes and course of physical disability in the one-third most disabled women living in the community. The main objective of this additional data collection is to obtain information on disability and nursing home admission

that will serve as end points in 5-year prospective analyses. This information will be a valuable addition to outcome data on death and hospital admissions that will be obtained through linkage with the National Death Index and the Health Care Financing Administration Medicare data base for this same period of time. The variables collected in the follow-up telephone assessments will provide important endpoints for a great many analyses that address the primary goal of the study, evaluating factors related to the progression of disability and need for long-term care. Frequency of Response: Once a year. Affected Public: Individuals or households. Type of Respondents: Women age 68 and older. Estimated Number of Respondents: 800; Estimated Number of Responses per Respondent: 2; Average Burden Hours Per Response: .33; Estimated Total Annual Burden Hours Requested: 267. The annualized cost to respondents is estimated at: \$2,664. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

REQUEST FOR COMMENTS: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the

proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Jack Guralnik, Chief Epidemiology and Demography Office, Epidemiology, Demography, and Biometry Program, NIA, NIH, Gateway Building, Room 3C309, 7201 Wisconsin Avenue MSC 9205, Bethesda, MD 20892–9205, or call non-toll-free number (301) 496–1178 or E-mail your request, including your address to: JG48S@nih.gov

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received on or before October 21, 1996.

Colleen Barros,

Executive Officer, NIA.
[FR Doc. 96–21126 Filed 8–19–96; 8:45 am]
BILLING CODE 4140–01–M

Submission for OMB Review; Comment Request; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

SUMMARY: Under the provisions of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the National Cancer Institute (NCI), the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request to review and approve the information collection listed below. This proposed information collection was previously published in the Federal Register on June 7, 1996, page 29106 and allowed 60-days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

PROPOSED COLLECTION: Title: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Type of Information